Inquis Medical today announced findings from the AVENTUS trial evaluating the safety and efficacy of its Aventus thrombectomy ...

ElectroCore (Nasdaq:ECOR) announced today that it completed its previously announced acquisition of NeuroMetrix  (Nasdaq:NURO ...

Rhythm Technologies (Nasdaq: IRTC) shares are on the rise on first-quarter results that were mixed compared to the Wall ...

Aktiia announced today that it raised an oversubscribed $42 million Series B funding round and introduced its new "Hilo" ...

The Financial Times reports today that histotripsy tech developer HistoSonics is considering a potential sale after receiving ...

Neuralink said on social media that it received FDA breakthrough device designation for treating individuals with severe ...

Stryker reported Street-beating financial results and upped its sales forecast, but said tariffs will decrease previously ...

The company reports that NUOS 3 can enable patients who have been declared clinically dead — at times for over 30 minutes — and later resuscitated to regain the ability to communicate. Despite ...

Element Science announced today that it received FDA pre-market approval for its Jewel patch wearable cardioverter ...

Baxter Chair and interim CEO Brent Shafer said some tariff mitigation activities are underway while others are being ...

CEO Jason Hollar said Cardinal Health is "engaging" with the Trump Administration "to try to mitigate impact to patient care.

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.